ALKERMES | ALKS - Current Assets


ALKERMES reported $1.58B in Current Assets for its fiscal quarter ending in September of 2026.





Current Assets Change Date
AbbVie USD 37.48B 3.81B Sep/2026
Acadia Pharmaceuticals USD 1.27B 43.88M Sep/2026
ALKERMES USD 1.58B 57.83M Sep/2026
Amgen USD 34.36B 598M Sep/2026
Biogen USD 7.58B 278.7M Sep/2026
BioMarin Pharmaceutical USD 3.92B 50.99M Sep/2026
Bristol-Myers Squibb USD 29.77B 1.19B Sep/2026
Coherus Biosciences USD 133.79M 72.25M Jun/2026
Eli Lilly USD 65.26B 591M Sep/2026
Gilead Sciences USD 16.55B 4.02B Sep/2026
Heron Therapeutics USD 209.11M 20.73M Sep/2026
Ionis Pharmaceuticals USD 2.36B 129.77M Sep/2026
J&J USD 56.35B 3.42B Sep/2026
Malin Corporation EUR 62.6M 26.7M Dec/2024
Merck USD 38.94B 2.26B Sep/2026
Minerva Neurosciences USD 83.1M 70.08M Dec/2025
Nektar Therapeutics USD 589.04M 322.77M Mar/2026
Neurocrine Biosciences USD 2.01B 370.7M Sep/2026
Otsuka Holdings JPY 1.6T 29.58B Sep/2026
Ovoca Bio EUR 2.07M 510K Dec/2025
Pfizer USD 45.01B 3.65B Sep/2026
Regeneron Pharmaceuticals USD 20.8B 2.35B Sep/2026
Vertex Pharmaceuticals USD 11.69B 857.4M Sep/2026